AR082953A1 - Metodos para tratar deficiencia de acido lisosomal lipasa en pacientes - Google Patents

Metodos para tratar deficiencia de acido lisosomal lipasa en pacientes

Info

Publication number
AR082953A1
AR082953A1 ARP110103302A ARP110103302A AR082953A1 AR 082953 A1 AR082953 A1 AR 082953A1 AR P110103302 A ARP110103302 A AR P110103302A AR P110103302 A ARP110103302 A AR P110103302A AR 082953 A1 AR082953 A1 AR 082953A1
Authority
AR
Argentina
Prior art keywords
therapeutic agent
methods
lal
lisosomal
lipasa
Prior art date
Application number
ARP110103302A
Other languages
English (en)
Inventor
Anthony Quinn
Original Assignee
Synageva Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45806910&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR082953(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2011/033699 external-priority patent/WO2011133960A2/en
Application filed by Synageva Biopharma Corp filed Critical Synageva Biopharma Corp
Publication of AR082953A1 publication Critical patent/AR082953A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01013—Sterol esterase (3.1.1.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Métodos para tratar deficiencias de ácido Iisosomal lipasa (LAL) que comprenden administrar a un mamífero una cantidad terapéuticamente eficaz de ácido lisosomal lipasa con una frecuencia de dosificación adecuada. También se proveen métodos para mejorar el crecimiento y la función hepática, aumentar la concentración de LAL en los tejidos, y aumentar la actividad de LAL en un paciente humano que padece una deficiencia de LAL.Reivindicación 53: El método de la reivindicación 52, en donde el segundo agente terapéutico es un fármaco reductor del colesterol. Reivindicación 54: El método de la reivindicación 53, en donde el segundo agente terapéutico es una estatina. Reivindicación 55: El método de la reivindicación 53, en donde el segundo agente terapéutico es ezetimibe. Reivindicación 57: El método de la reivindicación 52, en donde el segundo agente terapéutico es un antihistamínico. Reivindicación 58: El método de la reivindicación 52, en donde el segundo agente terapéutico es un inmunosupresor.
ARP110103302A 2010-09-09 2011-09-09 Metodos para tratar deficiencia de acido lisosomal lipasa en pacientes AR082953A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40301110P 2010-09-09 2010-09-09
US45601410P 2010-10-29 2010-10-29
US201161432372P 2011-01-13 2011-01-13
PCT/US2011/033699 WO2011133960A2 (en) 2010-04-23 2011-04-23 Lysosomal storage disease enzyme

Publications (1)

Publication Number Publication Date
AR082953A1 true AR082953A1 (es) 2013-01-23

Family

ID=45806910

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103302A AR082953A1 (es) 2010-09-09 2011-09-09 Metodos para tratar deficiencia de acido lisosomal lipasa en pacientes

Country Status (30)

Country Link
US (5) US8663631B2 (es)
EP (3) EP2613798B2 (es)
JP (3) JP5693728B2 (es)
KR (1) KR20150038636A (es)
CN (2) CN105457018A (es)
AR (1) AR082953A1 (es)
AU (1) AU2011314293B2 (es)
BR (2) BR122019021757B1 (es)
CA (2) CA3209456A1 (es)
CL (1) CL2013000664A1 (es)
CO (1) CO6710913A2 (es)
CY (1) CY1116544T1 (es)
DK (2) DK2613798T4 (es)
ES (2) ES2535605T5 (es)
HK (2) HK1220907A1 (es)
HR (1) HRP20150438T1 (es)
HU (1) HUE048688T2 (es)
IL (2) IL225095A (es)
ME (1) ME02062B (es)
MX (2) MX2013002704A (es)
NZ (3) NZ715014A (es)
PL (2) PL2613798T5 (es)
PT (2) PT2613798E (es)
RS (1) RS53947B1 (es)
RU (1) RU2550961C2 (es)
SG (2) SG10201507199UA (es)
SI (2) SI2977057T1 (es)
SM (1) SMT201500108B (es)
TW (1) TWI482625B (es)
WO (1) WO2012050695A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0108077A (pt) 2000-02-04 2002-10-22 Children S Hospital Res Founda Processo para reduzir placas ateroscleróticas em um mamìfero, método para tratamento da aterosclerose em um mamìfero, composição, métodos para prover proteìna ou polipeptìdeo hidrolisante de lipìdeo biologicamente ativo ou mistura deles, para células de um mamìfero tendo deficiência na proteìna ou polipeptìdeo hidrolisante de lipìdeo biologicamente ativo , para prover lipase de ácido lisossomal biologicamente ativa para células de um mamìfero tendo deficiência de lipase de ácido lisossomal biologicamente ativa, para prover lipase de ácido lisossoal biologicamente ativa para células de um mamìfero com aterosclerose, para tratamento da doença de wolman em um mamìfero, para tratamento de doença de armazenagem de colesteril éster em um mamìfero, e, para tratamento da aterosclerose em um mamìfero
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
MX338426B (es) * 2010-04-23 2016-04-15 Synageva Biopharma Corp Enzima de enfermedad del almacenamiento lisosomico.
EP2613798B2 (en) 2010-09-09 2018-01-24 Synageva BioPharma Corp. Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
WO2012112681A1 (en) 2011-02-15 2012-08-23 Shire Human Genetic Therapies, Inc. Methods for treating lysosomal acid lipase deficiency
JP6329483B2 (ja) 2011-10-12 2018-05-23 シナジェバ・バイオファーマ・コーポレイションＳｙｎａｇｅｖａ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐ． 組換えヒトｎａｇｌｕタンパク質およびその利用
EP2820032A4 (en) * 2012-03-02 2015-11-25 Synageva Biopharma Corp TRUNCATED LYSOSOMAL ACID LIPASE
CN106885910B (zh) * 2015-12-15 2018-12-21 上海吉涛生物科技有限公司 肿瘤易感微环境检测装置及试剂盒
US11235036B2 (en) 2016-06-17 2022-02-01 Alexion Pharmaceuticals, Inc. Lysosomal acid lipase deficiency compositions and methods
EP3504222A1 (en) 2016-08-23 2019-07-03 Alexion Pharmaceuticals, Inc. Method of purifying a heterologous protein from an egg white
US10633705B2 (en) 2016-10-14 2020-04-28 Alexion Pharmaceuticals, Inc. N-acetyl-alpha-D-glucosaminidase deficiency compositions and methods
US11396499B2 (en) 2018-12-12 2022-07-26 University Of Washington Lysosomal acid lipase assay
WO2021117122A1 (ja) * 2019-12-10 2021-06-17 株式会社リボルナバイオサイエンス ライソゾーム酸性リパーゼ欠損症の予防または治療剤

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9001985D0 (sv) 1990-06-01 1990-06-01 Astra Ab New chemical products
WO1992016212A1 (en) 1991-03-13 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Increasing the therapeutic efficiency of macrophage-targeted therapeutic agents by up-regulating the mannose lectin on macrophages
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AU3275595A (en) 1994-08-05 1996-03-04 Molecular/Structural Biotechnologies, Inc. Site-specific biomolecular complexes
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US5929304A (en) 1995-09-14 1999-07-27 Croptech Development Corporation Production of lysosomal enzymes in plant-based expression systems
AU4424497A (en) 1996-09-13 1998-04-02 Transkaryotic Therapies, Inc. Therapy for alpha-galactosidase a deficiency
IL135578A0 (en) 1997-10-29 2001-05-20 Genzyme Corp Compositions and methods for treating lysosomal storage disease
US20030166132A1 (en) 1998-08-26 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
KR20010101131A (ko) 1998-12-07 2001-11-14 추후기재 폼페병의 치료 방법
US7033780B1 (en) 1999-06-14 2006-04-25 Millennium Pharmaceuticals, Inc. Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
BR0108077A (pt) 2000-02-04 2002-10-22 Children S Hospital Res Founda Processo para reduzir placas ateroscleróticas em um mamìfero, método para tratamento da aterosclerose em um mamìfero, composição, métodos para prover proteìna ou polipeptìdeo hidrolisante de lipìdeo biologicamente ativo ou mistura deles, para células de um mamìfero tendo deficiência na proteìna ou polipeptìdeo hidrolisante de lipìdeo biologicamente ativo , para prover lipase de ácido lisossomal biologicamente ativa para células de um mamìfero tendo deficiência de lipase de ácido lisossomal biologicamente ativa, para prover lipase de ácido lisossoal biologicamente ativa para células de um mamìfero com aterosclerose, para tratamento da doença de wolman em um mamìfero, para tratamento de doença de armazenagem de colesteril éster em um mamìfero, e, para tratamento da aterosclerose em um mamìfero
WO2001097829A2 (en) 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
AU2002221755A1 (en) 2000-10-31 2002-05-15 Bayer Aktiengesellschaft Nucleotide and polypeptide sequence of human lysosomal acid lipase
US20030064437A1 (en) 2000-11-15 2003-04-03 Nick Wan Expression system for recombinant proteins
US20020193303A1 (en) 2001-01-25 2002-12-19 Millennium Pharmaceuticals, Inc. 58860, a human cholesteryl ester hydrolase and uses therefor
US6800472B2 (en) 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US20050181474A1 (en) 2002-01-30 2005-08-18 Frank J. Giordano Transport peptides and uses therefor
PT1495328E (pt) 2002-04-16 2014-09-09 Vlaams Interuniv Inst Biotech Um marcador para medir cirrose hepática
AU2003283976B2 (en) 2002-09-27 2009-12-10 Cold Spring Harbor Laboratory Cell-based RNA interference and related methods and compositions
US20050208090A1 (en) 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
US20070270364A1 (en) 2004-06-15 2007-11-22 Mayo Foundation For Medical Education And Research Helicases
WO2006023782A2 (en) 2004-08-19 2006-03-02 Biogen Ideca Ma Inc. Refolding transforming growth factor beta family proteins
US20070270367A1 (en) 2005-05-18 2007-11-22 University Of Kentucky Research Foundation Rybozyme-catalyzed insertion of targeted sequences into RNA
US20090297496A1 (en) 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
PL377180A1 (pl) 2005-09-21 2007-04-02 Instytut Farmaceutyczny Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
US7524626B2 (en) 2005-10-05 2009-04-28 Synageva Biopharma Corp. Rapid production of high titer virus
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US20070267249A1 (en) 2006-05-18 2007-11-22 Cullen David P Roof safety system
US8748567B2 (en) 2006-05-22 2014-06-10 Children's Medical Center Corporation Method for delivery across the blood brain barrier
CA2653456A1 (en) 2006-05-24 2007-11-29 Richard Daneman Permeability of blood-brain barrier
US8143265B2 (en) 2007-04-16 2012-03-27 Meharry Medical College Method of treating atherosclerosis
WO2008131431A2 (en) 2007-04-23 2008-10-30 St. Louis University Modulation of blood brain barrier protein expression
EP3486653A1 (en) 2007-05-24 2019-05-22 The United States Government as represented by The Department of Veterans Affairs Treatment of skeletal muscle disorder using ent2
AU2008255565B2 (en) 2007-05-31 2013-10-24 Paradigm Biopharmaceuticals Ltd Sulphated xylans for treatment or prophylaxis of respiratory diseases
JP2010533170A (ja) 2007-07-12 2010-10-21 プロセンサ テクノロジーズ ビー．ブイ． 化合物を種々の選択された臓器、組織又は腫瘍細胞に標的化するための分子
EP2185187A1 (en) 2007-08-29 2010-05-19 Shire Human Genetic Therapies, Inc. Subcutaneous administration of alpha-galatosidase a
KR101343485B1 (ko) 2008-01-07 2013-12-20 시나게바 바이오파르마, 코포레이션 조류에서의 당화
WO2010033854A2 (en) 2008-09-19 2010-03-25 Synageva Biopharma Corp. Avian derived fusion proteins
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
WO2010078515A2 (en) 2009-01-02 2010-07-08 Zacharon Pharmaceuticals, Inc. Polymer end group detection
US8232073B2 (en) 2009-01-02 2012-07-31 Zacharon Pharmaceuticals, Inc. Quantification of non-reducing end glycan residual compounds
WO2011000958A1 (en) 2009-07-03 2011-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Compounds targeting the cation-independent mannose 6-phosphate receptor
US20110033699A1 (en) 2009-07-23 2011-02-10 Nitto Denko Corporation Pressure-sensitive adhesive tape
HUE028129T2 (en) 2009-10-19 2016-11-28 Amicus Therapeutics Inc New preparations for the prevention and / or treatment of lysosomal storage disorders
KR101077618B1 (ko) 2009-11-13 2011-10-27 경북대학교 산학협력단 뇌혈관 장벽을 통과하여 퇴행성 뇌신경 질환 부위의 세포사멸을 표적하는 펩타이드 및 이의 용도
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
WO2011113027A2 (en) 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
MX338426B (es) 2010-04-23 2016-04-15 Synageva Biopharma Corp Enzima de enfermedad del almacenamiento lisosomico.
US20150030582A1 (en) 2010-04-23 2015-01-29 Synageva Biopharma Corp. Lysosomal Storage Disease Enzyme
EP2613798B2 (en) 2010-09-09 2018-01-24 Synageva BioPharma Corp. Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
WO2012112681A1 (en) 2011-02-15 2012-08-23 Shire Human Genetic Therapies, Inc. Methods for treating lysosomal acid lipase deficiency
WO2012112677A2 (en) 2011-02-15 2012-08-23 Children's Hospital Medical Center Methods for treating lysosomal acid lipase deficiency
JP6091435B2 (ja) 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達
EP2709670A4 (en) 2011-05-18 2015-01-21 Childrens Hosp Medical Center TARGETED ADMINISTRATION OF PROTEINS ACROSS THE HEMATO-ENCEPHALIC BARRIER
WO2012177778A1 (en) 2011-06-20 2012-12-27 Mount Sinai School Of Medicine Anti-tnf- therapy for the mucopolysaccharidoses and other lysosomal disorders
WO2012177639A2 (en) 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
US20130027021A1 (en) 2011-07-28 2013-01-31 Abb Inc. Current sensor
JP2014524241A (ja) 2011-08-03 2014-09-22 ロータス ティシュー リペア インコーポレイテッド コラーゲン７及び関連する方法
JP6329483B2 (ja) 2011-10-12 2018-05-23 シナジェバ・バイオファーマ・コーポレイションＳｙｎａｇｅｖａ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐ． 組換えヒトｎａｇｌｕタンパク質およびその利用

Also Published As

Publication number Publication date
SI2977057T1 (sl) 2020-03-31
SI2613798T2 (en) 2018-05-31
CN105457018A (zh) 2016-04-06
CO6710913A2 (es) 2013-07-15
US8663631B2 (en) 2014-03-04
SG188456A1 (en) 2013-04-30
MX365007B (es) 2019-05-20
MX2013002704A (es) 2013-09-13
RU2013110491A (ru) 2014-11-10
US20190282671A1 (en) 2019-09-19
CN103200958A (zh) 2013-07-10
HK1215532A1 (zh) 2016-09-02
SI2613798T1 (sl) 2015-05-29
US20160051638A1 (en) 2016-02-25
EP2977057B1 (en) 2019-11-06
RS53947B1 (en) 2015-08-31
BR122019021757B1 (pt) 2020-12-08
SG10201507199UA (en) 2015-10-29
PT2613798E (pt) 2015-06-02
NZ715014A (en) 2018-10-26
BR112013005673B1 (pt) 2020-12-15
TW201225971A (en) 2012-07-01
SMT201500108B (it) 2015-07-09
IL245283A0 (en) 2016-06-30
EP2613798B2 (en) 2018-01-24
WO2012050695A1 (en) 2012-04-19
DK2613798T4 (en) 2018-04-16
PL2613798T3 (pl) 2015-07-31
TWI482625B (zh) 2015-05-01
US20220362350A1 (en) 2022-11-17
CA2810999C (en) 2023-10-03
PT2977057T (pt) 2020-02-18
CY1116544T1 (el) 2018-03-07
BR112013005673A2 (pt) 2017-09-19
EP2977057A1 (en) 2016-01-27
JP2013540733A (ja) 2013-11-07
PL2977057T3 (pl) 2020-06-01
AU2011314293B2 (en) 2015-06-04
DK2977057T3 (da) 2020-02-10
KR20150038636A (ko) 2015-04-08
JP2016145257A (ja) 2016-08-12
HUE048688T2 (hu) 2020-08-28
CL2013000664A1 (es) 2013-10-04
ES2769836T3 (es) 2020-06-29
RU2550961C2 (ru) 2015-05-20
IL225095A (en) 2016-05-31
CA3209456A1 (en) 2012-04-19
IL245283B (en) 2019-02-28
CA2810999A1 (en) 2012-04-19
NZ700824A (en) 2016-03-31
US11400141B2 (en) 2022-08-02
DK2613798T3 (en) 2015-04-20
JP2015052014A (ja) 2015-03-19
ES2535605T3 (es) 2015-05-13
JP6156882B2 (ja) 2017-07-05
AU2011314293A1 (en) 2013-04-04
EP2613798B1 (en) 2015-02-11
NZ608292A (en) 2014-10-31
HRP20150438T1 (hr) 2015-05-22
EP3650039A1 (en) 2020-05-13
HK1220907A1 (zh) 2017-05-19
US10166274B2 (en) 2019-01-01
US20140348752A1 (en) 2014-11-27
PL2613798T5 (pl) 2018-06-29
EP2613798A1 (en) 2013-07-17
ME02062B (me) 2015-05-20
JP5693728B2 (ja) 2015-04-01
US20120064055A1 (en) 2012-03-15
ES2535605T5 (es) 2018-04-30

Similar Documents

Publication Publication Date Title
AR082953A1 (es) Metodos para tratar deficiencia de acido lisosomal lipasa en pacientes
BR112013004917A2 (pt) terapias de células tronco alogênicas sistêmicas para tratamento de doenças em animais.
EP4327882A3 (en) Enpp1 inhibitors and their use for the treatment of cancer
NZ720946A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
NZ605865A (en) Cns delivery of therapeutic agents
MX2009012197A (es) Metodos para tratamiento de ulceras en la piel.
RU2017125281A (ru) Доставка терапевтических агентов в цнс
AR055038A1 (es) Metodo y compuesto para tratar enfermedades vasculares perifericas
EA200970360A1 (ru) Омега-3 жирные кислоты и средство для лечения дислипидемии для снижения уровней аро-в
MX2009005341A (es) Sistema terapeutico transdermico para administrar la sustancia activa buprenorfina.
WO2013100818A3 (en) A biocomposite for regeneration of injured tissue and organs, a kit for making the biocomposite, a method of making the biocomposite and a method of treating inquiries.
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
Rogers et al. The use of marrow‐derived stem cells to accelerate healing in chronic wounds
EA201001853A1 (ru) Фармацевтическая комбинация
WO2010107251A2 (ko) 파카스트리사민을 유효성분으로 함유하는 과증식성 피부질환과 악성흑생종의 예방 또는 치료용 약학적 조성물
TW200833345A (en) Use of vitamin D compounds and mimics thereof to enhance delivery of therapeutics and oxygen to tumors and other tissues
RU2014129514A (ru) [1,2,4]триазолопиридины и их применение в качестве ингибиторов фосфодиэстеразы
Huang et al. Physical therapy in diabetic foot ulcer: Research progress and clinical application
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
PT1585513E (pt) Utilizacao de acido docosa-hexaenoico como substancia activa para o tratamento de lipodistrofia
EA201270551A1 (ru) Лечение нейротоксичности, ассоциированной с комбинациями 5-fu или его пролекарств с ингибиторами dpd
RU2557949C1 (ru) Способ лечения лучевого и интерстициального цистита
CN211273205U (zh) 用于防控呼吸道传染病的多光束体外照射装置
CN104436192A (zh) 5-氨基酮戊酸在制备声动力治疗动脉粥样硬化药物中的应用
WO2011156715A3 (en) Methods of treating metabolic disorders and cardiovascular diseases

Legal Events

Date Code Title Description
FB Suspension of granting procedure